CanSino Biologics Inc. (6185.HK)
HKD 33.5
(-1.33%)
HKD 33.5
(-1.33%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -876.01 Million CNY | -369.45% |
| 2022 | -186.6 Million CNY | -106.21% |
| 2021 | 3 Billion CNY | 63258.99% |
| 2020 | 4.74 Million CNY | 121.92% |
| 2019 | 2.13 Million CNY | 101.9% |
| 2018 | -112.51 Million CNY | -90.97% |
| 2017 | -58.91 Million CNY | -35.53% |
| 2016 | -43.47 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 119.1 Million CNY | 75.02% |
| 2024 Q1 | 68.04 Million CNY | 107.74% |
| 2023 Q2 | -811.85 Million CNY | -2395.54% |
| 2023 Q1 | 35.36 Million CNY | 105.42% |
| 2023 FY | -876.01 Million CNY | -369.45% |
| 2023 Q4 | -878.93 Million CNY | -212.77% |
| 2023 Q3 | 779.4 Million CNY | 196.0% |
| 2022 Q3 | 149.53 Million CNY | 530.85% |
| 2022 Q4 | -652.31 Million CNY | -536.22% |
| 2022 Q1 | 350.88 Million CNY | -63.55% |
| 2022 Q2 | -34.7 Million CNY | -109.89% |
| 2022 FY | -186.6 Million CNY | -106.21% |
| 2021 Q4 | 962.76 Million CNY | 59.66% |
| 2021 FY | 3 Billion CNY | 63258.99% |
| 2021 Q1 | 242.71 Million CNY | 4765.36% |
| 2021 Q3 | 603.01 Million CNY | -49.47% |
| 2021 Q2 | 1.19 Billion CNY | 391.71% |
| 2020 Q3 | 1.48 Million CNY | 0.0% |
| 2020 FY | 4.74 Million CNY | 121.92% |
| 2020 Q2 | - CNY | -100.0% |
| 2020 Q1 | 3.68 Million CNY | 993.25% |
| 2020 Q4 | 4.98 Million CNY | 236.23% |
| 2019 Q3 | 20.43 Thousand CNY | -98.36% |
| 2019 FY | 2.13 Million CNY | 101.9% |
| 2019 Q2 | 1.24 Million CNY | 134.48% |
| 2019 Q1 | 531.65 Thousand CNY | 101.58% |
| 2019 Q4 | 337.22 Thousand CNY | 1550.3% |
| 2018 Q1 | -28.12 Million CNY | 0.0% |
| 2018 Q3 | 4.32 Million CNY | 115.39% |
| 2018 Q4 | -33.6 Million CNY | -876.54% |
| 2018 FY | -112.51 Million CNY | -90.97% |
| 2018 Q2 | -28.12 Million CNY | 0.0% |
| 2017 Q2 | -17.02 Million CNY | 0.0% |
| 2017 Q4 | -28.12 Million CNY | 0.0% |
| 2017 FY | -58.91 Million CNY | -35.53% |
| 2017 Q1 | -17.02 Million CNY | 0.0% |
| 2016 Q1 | -12.91 Million CNY | 0.0% |
| 2016 FY | -43.47 Million CNY | 0.0% |
| 2016 Q4 | -17.02 Million CNY | 0.0% |
| 2016 Q2 | -12.91 Million CNY | 0.0% |
| 2015 Q4 | -12.91 Million CNY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 167.43 Million HKD | 623.196% |
| Grand Pharmaceutical Group Limited | 6.52 Billion HKD | 113.428% |
| Extrawell Pharmaceutical Holdings Limited | 28.77 Million HKD | 3143.952% |
| Wai Yuen Tong Medicine Holdings Limited | 394.81 Million HKD | 321.882% |
| Qianhai Health Holdings Limited | -35.6 Million HKD | -2360.52% |
| Lee's Pharmaceutical Holdings Limited | 551.31 Million HKD | 258.897% |
| Essex Bio-Technology Limited | 1.53 Billion HKD | 156.91% |
| Tongfang Kontafarma Holdings Limited | 471.29 Million HKD | 285.876% |
| PuraPharm Corporation Limited | 216.62 Million HKD | 504.387% |
| SSY Group Limited | 3.48 Billion HKD | 125.107% |
| JBM (Healthcare) Limited | 319.41 Million HKD | 374.256% |
| Jacobson Pharma Corporation Limited | 620.47 Million HKD | 241.185% |
| China Resources Pharmaceutical Group Limited | 43.36 Billion HKD | 102.02% |